The same group demonstrated that lung-targeted adenovirus-mediated BMPR2 gene therapy significantly reduced the RV hypertrophy as well as the PAP in the MCT-induced PAH model in rats [151]. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.